Table 2. Diagnostic Testing.
| Placebo (n=8,696) |
Vitamin E alone (n=8,737) |
Selenium alone (n=8,752) |
Vitamin E + selenium (n=8,702) |
|
|---|---|---|---|---|
| Prostate biopsy (men ever having biopsy) | ||||
| Prior to unblinding1 | 1,041 | 1,046 | 1,003 | 1,014 |
| Post unblinding | 256 | 268 | 267 | 254 |
| Number of DREs/participant | ||||
| Prior to unblinding | 3.20 | 3.20 | 3.20 | 3.21 |
| Post unblinding | 0.64 | 0.63 | 0.64 | 0.64 |
| Number of PSA tests/participant | ||||
| Prior to unblinding | 3.87 | 3.88 | 3.87 | 3.90 |
| Post unblinding | 0.84 | 0.85 | 0.86 | 0.86 |
| Geometric mean PSA (95% CI) | ||||
| Year 0 | 1.13 (0.24, 4.41) | 1.12 (0.23, 4.37) | 1.12 (0.23, 4.41) | 1.13 (0.23, 4.42) |
| Year 1 | 1.16 (0.22, 4.82) | 1.14(0.21, 4.75) | 1.14 (0.21, 4.89) | 1.15 (0.21, 4.91) |
| Year 2 | 1.18 (0.21, 5.08) | 1.15 (0.21, 4.95) | 1.17 (0.21, 5.12) | 1.16 (0.21, 5.08) |
| Year 3 | 1.19 (0.21, 5.25) | 1.17 (0.20, 5.26) | 1.20 (0.21, 5.31) | 1.19 (0.21, 5.25) |
| Year 4 | 1.23 (0.21,5.62) | 1.19 (0.20, 5.40) | 1.23 (0.21, 5.61) | 1.23 (0.21, 5.62) |
| Year 5 | 1.25 (0.21, 5.81) | 1.23 (0.21, 5.62) | 1.26 (0.21, 5.89) | 1.23 (0.21, 5.81) |
| Year 6 | 1.28 (0.21, 6.03) | 1.23 (0.20, 5.83) | 1.26 (0.20, 5.98) | 1.25 (0.21, 6.03) |
| Year 7 | 1.30 (0.21, 6.27) | 1.26 (0.21, 5.91) | 1.30 (0.21, 6.22) | 1.28 (0.21, 6.27) |
| Year 8 | 1.31 (0.20, 6.52) | 1.29 (0.20, 6.30) | 1.39 (0.23, 6.59) | 1.35 (0.20, 6.52) |
| PSA velocity Year 0 – Year 1 median (Q1, Q3) | 0 (-0.20, 0.30) | 0 (-0.20, 0.22) | 0 (-0.20, 0.28) | 0 (-0.20, 0.30) |
1
Trial was unblinded on October 23, 2008. Data in the primary paper are as of this date.